Your U.S.- Based Bioconjugation Partner

Developing antibody–drug conjugates demands tight control across antibody production, conjugation, and quality systems. A single‑site manufacturing model brings these capabilities together, reducing handoffs that can introduce delay, risk, and variability. This facility overview highlights integrated mAb production and bioconjugation supported by scalable cGMP manufacturing, high‑potency containment, and in‑house analytical and regulatory expertise. Flexible production volumes support both clinical and commercial programs, while an end‑to‑end service model enables continuity from early process development through ongoing verification. The facility is designed to handle a wide range of conjugation modalities and formats, helping teams adapt as programs evolve. By simplifying supply chains and aligning quality systems across operations, the approach offers a practical path to faster execution, improved compliance, and more predictable outcomes for ADC programs navigating increasing technical and regulatory complexity.